We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Tumor Suppressor Found to Stimulate Growth of Anaplastic Thyroid Cancer Cells

By LabMedica International staff writers
Posted on 04 Jul 2012
Print article
Cancer researchers have found that the tumor suppressing protein FOXO3a (a Forkhead transcription factor) behaves like a tumor enhancer in human anaplastic thyroid cancer (ATC) cells.

ATC is a serious health threat, since while it accounts for just 2% percent of thyroid cancer cases in the US it is responsible for about 40% of thyroid cancer deaths.

Investigators at the Mayo Clinic (Jacksonville, FL, USA) evaluated the effect of an Akt (protein kinase B) blocker - similar to the ones now being tested in human cancer clinical trials – on cultures of ATC cells.

The data they obtained was both unexpected and worrying. They reported in the June 20, 2012, online edition of the Journal of Cell Science that blocking Akt – which was supposed to inhibit cancer cell growth – stimulated the growth of ATC cells.

In most types of cancers, FoxO3a is phosphorylated by Akt, resulting in its exclusion from the nucleus. Removed from the nucleus FOXO3a cannot block cell growth. However, in ATC cells FoxO3a remains nuclear. This nuclear FoxO3a promotes cell cycle progression by transcriptional upregulation of cyclin A1, promoting proliferation of human ATC cells. On the other hand, silencing FoxO3a with a reverse genetics approach led to down-regulation of CCNA1 (cyclin A1) mRNA and protein.

“This result is exactly the opposite of what we expected,” said senior author Dr. John A. Copland, professor of cancer biology at the May Clinic. “We were more than surprised. We were concerned. Cancer researchers, including those testing Akt inhibitors, should know that FOXO3a has pro-cancer activity as well as anticancer properties. Concern should be raised that an Akt inhibitor will enhance retention of FOXO3a in the nucleus, causing FOXO3a to remain active.

Related Links:
Mayo Clinic


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: The QIAstat-Dx Respiratory Panel Plus has received U.S. FDA clearance (Photo courtesy of QIAGEN)

New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results

Respiratory tract infections are a major reason for emergency department visits and hospitalizations. According to the CDC, the U.S. sees up to 41 million influenza cases annually, resulting in several... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more